Articles by Daniel Marsh
AT&T Stock Rebounds After $23B Spectrum Deal, Debt Concerns Loom
AT&T shares rebounded 0.7% to $23.38 after a two-day slide, following its $23B spectrum acquisition from EchoStar. The deal adds $14.5B in short-term debt, with leverage expected to peak at 3.2x.
Mangoceuticals Rockets 173% on Nuclear Merger; Existing Holders Left with 4%
Mangoceuticals (MGRX) shares soared 173.5% to $0.8029 after announcing a reverse merger with Nuclea Energy, with existing shareholders retaining only 4% pre-PIPE.
Tesla Stock Retreats as Shanghai Export Reliance Raises Investor Concerns
Tesla shares gave up early gains after Elon Musk dismissed a report about splitting China operations, but concerns over Shanghai's export dependence and margin pressures persist.
Novo Nordisk Shares Plunge 9% as ZEUS Trial Fails to Show Cardiovascular Benefit
Novo Nordisk shares fell sharply after ZEUS trial data showed no significant cardiovascular benefit, wiping out $20.5 billion in market cap and underscoring heavy reliance on GLP-1 franchise.
Replimune Rockets 131% on FDA Panel Backing for RP1
Replimune shares jumped 131% to $12.50 after an FDA panel voted 10-3 that RP1's efficacy data is interpretable and clinically important, adding nearly $600 million in market value.
SpaceX Lands $1.6B Space Force Deal, Yet Stock Slips
SpaceX won a $1.6B Space Force contract for 18 Falcon 9 launches, but the stock slipped 0.3% as investors weigh Starlink and AI prospects ahead of Q2 earnings.
